# A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Source: https://onco.cc/trials/nct07448922/  
OnCo record `nct07448922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin and Bevacizumab in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT07448922 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 280 participants planned, started 2026-04-08 and due to reach its primary completion in 2027-12-31. Interventions recorded: SKB518 for injection, Carboplatin (AUC 5) and Bevacizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07448922
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignancies
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT07448922: https://clinicaltrials.gov/study/NCT07448922

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07448922.json